

GAU 1816

LUD 5 5-JEL/NDH

#8 Election / Amended
1/2/97 DW!

I hereby certify that this correspondence
is being deposited with the United States
Patent and Trademark Office as first class mail in an
envelope addressed to: Commissioner of
Patents and Trademarks, Washington, D.C.
20231, on December 5, 1997.

FELFE & LYNCH

By

Pauline Smith

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Thierry Boon-Falleur et al.
Serial No. : 08/819,669
Filed : March 17, 1997
For : TUMOR REJECTION ANTIGEN PRECURSORS/
TUMOR REJECTION ANTIGENS AND USES
THEREOF
Art Unit : 1816
Examiner : T. Cunningham

RECEIVED
DEC 13 1997
GROUP 1800

December 5, 1997

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the restriction requirement of November 10,
applicants elect Group I, i.e., claims 173-177.

Claims 173, 174 and 177, however, are not drawn, specifically
to MAGE-1. Claims 173 and 174 are generic, and claim 177 is
subgeneric. SEQ ID NO: 8 encodes MAGE-1, so claim 175 is drawn to
MAGE-1.

It appears that the Examiner was trying to set forth a genus-species restriction requirement. On this assumption, applicants elect the species MAGE-1, and the claims readable thereon are claims 173-177. Please note the accompanying preliminary amendment.

The informalities regarding the oath are noted. These will be addressed following an indication of allowable subject matter.

Respectfully submitted,

FELFE & LYNCH

By 

Norman D. Hanson
Reg. No. 30,946

805 Third Avenue
New York, New York 10022
(212) 688-9200